Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood.
dc.contributor.author | Zhou, Hongyan | |
dc.contributor.author | Martinez, Hector | |
dc.contributor.author | Sun, Bruce | |
dc.contributor.author | Li, Aiqun | |
dc.contributor.author | Zimmer, Matthew | |
dc.contributor.author | Katsanis, Nicholas | |
dc.contributor.author | Davis, Erica E | |
dc.contributor.author | Kurtzberg, Joanne | |
dc.contributor.author | Lipnick, Scott | |
dc.contributor.author | Noggle, Scott | |
dc.contributor.author | Rao, Mahendra | |
dc.contributor.author | Chang, Stephen | |
dc.date.accessioned | 2022-03-23T19:02:40Z | |
dc.date.available | 2022-03-23T19:02:40Z | |
dc.date.issued | 2015-08 | |
dc.date.updated | 2022-03-23T19:02:39Z | |
dc.description.abstract | Human peripheral blood and umbilical cord blood represent attractive sources of cells for reprogramming to induced pluripotent stem cells (iPSCs). However, to date, most of the blood-derived iPSCs were generated using either integrating methods or starting from T-lymphocytes that have genomic rearrangements thus bearing uncertain consequences when using iPSC-derived lineages for disease modeling and cell therapies. Recently, both peripheral blood and cord blood cells have been reprogrammed into transgene-free iPSC using the Sendai viral vector. Here we demonstrate that peripheral blood can be utilized for medium-throughput iPSC production without the need to maintain cell culture prior to reprogramming induction. Cell reprogramming can also be accomplished with as little as 3000 previously cryopreserved cord blood cells under feeder-free and chemically defined Xeno-free conditions that are compliant with standard Good Manufacturing Practice (GMP) regulations. The first iPSC colonies appear 2-3 weeks faster in comparison to previous reports. Notably, these peripheral blood- and cord blood-derived iPSCs are free of detectable immunoglobulin heavy chain (IGH) and T cell receptor (TCR) gene rearrangements, suggesting they did not originate from B- or T- lymphoid cells. The iPSCs are pluripotent as evaluated by the scorecard assay and in vitro multi lineage functional cell differentiation. Our data show that small volumes of cryopreserved peripheral blood or cord blood cells can be reprogrammed efficiently at a convenient, cost effective and scalable way. In summary, our method expands the reprogramming potential of limited or archived samples either stored at blood banks or obtained from pediatric populations that cannot easily provide large quantities of peripheral blood or a skin biopsy. | |
dc.identifier.issn | 2629-3269 | |
dc.identifier.issn | 2629-3277 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | Stem cell reviews and reports | |
dc.relation.isversionof | 10.1007/s12015-015-9586-8 | |
dc.subject | Leukocytes, Mononuclear | |
dc.subject | Pluripotent Stem Cells | |
dc.subject | Fetal Blood | |
dc.subject | Humans | |
dc.subject | Sendai virus | |
dc.subject | Receptors, Transferrin | |
dc.subject | Proto-Oncogene Proteins c-myc | |
dc.subject | Antigens, CD | |
dc.subject | Cryopreservation | |
dc.subject | Cell Culture Techniques | |
dc.subject | Immunohistochemistry | |
dc.subject | Cell Differentiation | |
dc.subject | Gene Expression | |
dc.subject | Cell Lineage | |
dc.subject | Transgenes | |
dc.subject | Genetic Vectors | |
dc.subject | Blood Donors | |
dc.subject | Octamer Transcription Factor-3 | |
dc.subject | Kruppel-Like Transcription Factors | |
dc.subject | SOXB1 Transcription Factors | |
dc.subject | Induced Pluripotent Stem Cells | |
dc.subject | Cellular Reprogramming | |
dc.subject | Biomarkers | |
dc.subject | CD13 Antigens | |
dc.subject | Kruppel-Like Factor 4 | |
dc.title | Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood. | |
dc.type | Journal article | |
duke.contributor.orcid | Davis, Erica E|0000-0002-2412-8397 | |
duke.contributor.orcid | Kurtzberg, Joanne|0000-0002-3370-0703 | |
pubs.begin-page | 652 | |
pubs.end-page | 665 | |
pubs.issue | 4 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Faculty | |
pubs.organisational-group | Basic Science Departments | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Cell Biology | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Initiatives | |
pubs.organisational-group | Duke Innovation & Entrepreneurship | |
pubs.organisational-group | Pediatrics, Transplant and Cellular Therapy | |
pubs.publication-status | Published | |
pubs.volume | 11 |
Files
Original bundle
- Name:
- p299 Zhou.pdf
- Size:
- 5.96 MB
- Format:
- Adobe Portable Document Format
- Description:
- Published version